Drugs / sofosbuvir/velpatasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03891550 | May 2019 → Apr 2024 | hepatitis C virus infection | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sofosbuvir/velpatasvir | “12 weeks of sofosbuvir/velpatasvir, in each individual hemodialysis center (Erase-C campaign) to achieve HCV micro-elimination.” NCT03891550 ↗ |
| Action | Inhibit | “HCV non-structural 5A (NS5A) inhibitor and NS5B inhibitor” NCT03891550 ↗ |
| Route | Oral | “all oral” NCT03891550 ↗ |